Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesThe use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS
Journal of Affective Disorders, 06/22/09
Kelly T et al. - A high percentage of bipolar II and bipolar NOS patients with treatment resistant depression improved on T3. Despite the use of higher than usual doses in many of the patients, the medication was well tolerated. Augmentation with supraphysiologic doses of T3 should be considered in cases of treatment resistant bipolar depression.
Methods- Retrospective chart review of patients treated in a private clinic between 2002 and 2006.
- The charts of 125 patients with bipolar II disorder and 34 patients with bipolar disorder NOS were reviewed.
- Patients had been unsuccessfully treated with an average of 14 other medications before starting T3.
- At an average dose of 90.4 mcg (range 13 mcg–188 mcg) the medication was well tolerated.
- None of the patients experienced a switch into hypomania, and only 16 discontinued due to side effects.
- Improvement was experienced by 84%, and 33% experienced full remission.
Today in Mental Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
Article Search
Sponsor